Early-stage lung cancer in elderly patients: A population-based study of changes in treatment patterns and survival in the Netherlands

• Published in: Annals of oncology Vol. 23; no. 10; pp. 2743 - 2747
• Main Authors: Haasbeek, C.J.A., Palma, D., Visser, O., Lagerwaard, F.J., Slotman, B., Senan, S.
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 01-10-2012; Oxford University Press
• Subjects: Aged; Antineoplastic agents; Biological and medical sciences; elderly; epidemiology; Humans; lung cancer; Lung Neoplasms - epidemiology; Lung Neoplasms - therapy; Medical sciences; Netherlands - epidemiology; Pharmacology. Drug treatments; Pneumology; Registries; SABR; SBRT; stereotactic radiotherapy; Survival Rate; Tumors of the respiratory system and mediastinum; Netherlands; Europe; lung cancer; SABR; epidemiology; stereotactic radiotherapy; elderly; SBRT; Human; Lung disease; Respiratory disease; Lung cancer; Radiosurgery; Patient; Early stage; Malignant tumor; Radiotherapy; Epidemiology; Survival; Bronchopulmonary; Treatment; Bronchus disease; Elderly; Public health; Cancer
• ISSN: 0923-7534; 1569-8041
• DOI: 10.1093/annonc/mds081

Elderly patients with stage I non-small-cell lung cancer are less likely to undergo curative treatment. However, the introduction of new treatment options such as stereotactic ablative radiotherapy (SABR) may improve treatment rates. We evaluated time trends in treatment patterns and survival in the entire Netherlands population for patients diagnosed between 2001 and 2009.
Details of 4605 elderly Dutch patients were obtained from the Netherlands Cancer Registry, containing data on all cancer patients in a population of 16 million. Three consecutive time periods were studied: 2001–2003 (A, before SABR became available), 2004–2006 (B, increasing availability), and 2007–2009 (C, full availability).
Between period A and C, there was a 7% absolute reduction in patients going untreated, corresponding to an 8-month improvement in median survival (P < 0.001). Radiotherapy utilization increased from 31% to 38%, whereas surgical utilization remained constant (37%). Significant improvements in survival were observed in the radiotherapy subgroup (P < 0.001) and surgery subgroup (P < 0.001), not in patients going untreated. There was no evidence of stage migration.
Population-based increases in survival of elderly stage I lung cancer patients were seen between 2001 and 2009. The introduction of SABR correlated with a decline in the number of untreated patients.